11.2 Drugs, Biologicals, J-Codes, and C-Codes

11.2 Drugs, Biologicals, J-Codes, and C-Codes

Quick Answer: Convert the documented dose using the HCPCS unit (J0690 = 500 mg; J2405 = 1 mg), then check OPPS Addendum B. CY 2026 packages most drugs at a $140 per-day threshold (status indicator N). Separately payable drugs use G (pass-through) or K (non-pass-through). JW bills discarded units from a single-dose container on a second line; JZ attests that nothing was discarded. Packaged drugs do not take JW or JZ.

Independent OpenExamPrep teaching for COC candidates treats hospital outpatient drug coding as both a HCPCS skill and an OPPS payment skill. Getting the J-code right is not enough if the status indicator says the line is packaged, and getting the status indicator right is not enough if the units are wrong.

Why medications are a COC HCPCS target

AAPC lists medications among the four HCPCS Level II question themes. In the HOPD and ASC, medications appear as peri-operative prophylaxis, antiemetics, infusions incident to a clinic visit, imaging-related drugs, and high-cost separately payable biologicals. The same J-code can be packaged in OPPS and separately payable on a physician-office claim. COC is the facility exam, so default to the OPPS lens.

J-codes: identification and unit conversion

J-codes describe drugs administered by a route other than oral, with specific oral exceptions listed in the tabular section (certain oral anti-cancer and anti-emetic agents among them). Identification starts in the Table of Drugs and is confirmed in the tabular list.

Two well-known codes illustrate the unit rule without inventing descriptors:

If the documentation says one gram of cefazolin, do not report 1 unit because a one-gram vial was opened, and do not report 1000 units because the dose was 1000 mg. Divide the dose by the published unit. If the Table of Drugs and the tabular descriptor disagree with a memory of last year's unit, trust the current book—CMS changes dosage descriptors.

Not-otherwise-classified (NOC) drug codes exist for products that lack a specific J-code. NOC lines require a narrative drug name, dose, and often NDC. In the physician office, JW and JZ still apply to single-dose-container NOC drugs. Under OPPS, CMS has stated that the JW/JZ requirement does not apply to C9399, which carries status indicator A. Do not invent a specific J-code when the book still points to NOC; do not use NOC when a specific code exists.

C-codes for OPPS drugs and devices

C-codes are temporary HCPCS Level II codes created for the hospital outpatient setting. Some describe pass-through or packaged devices; others describe drugs and biologicals before (or instead of) a permanent J- or Q-code. Hospitals and ASCs report C-codes on the institutional claim. Do not assume a professional coder should copy a C-code onto the CMS-1500 simply because the hospital used it.

When a drug has both a C-code and a J-code over time, follow the current OPPS Addendum B assignment for the date of service. Quarterly OPPS updates add, delete, and move drug codes among status indicators G, K, and N. CY 2026 January OPPS instructions (MM14361) created new pass-through drug codes, ended pass-through on others (those codes typically move from G to K), and changed status indicators on a large set of drug HCPCS lines. The exam will not require you to memorize the quarterly add/delete list; it will require you to know that the status indicator is date-specific and that pass-through is temporary.

OPPS status indicators G, K, and N

Read drugs through Addendum B, not through the HCPCS book alone.

For CY 2026, CMS finalized a packaging threshold of $140 for drugs, biologicals, and therapeutic radiopharmaceuticals. Products with a per-day cost at or below that threshold package (N). Products above the threshold are separately payable (typically K unless they have pass-through G). Diagnostic radiopharmaceuticals use a different CY 2026 threshold of $655; do not mix that figure with the $140 drug threshold.

Inexpensive peri-operative agents such as cefazolin (J0690) and ondansetron (J2405) often fall below $140 per day and therefore commonly package. Confirm the current Addendum B line rather than assuming a status indicator from a prior year. High-cost biologicals and many chemotherapy agents are separately payable. Pass-through G is a statutory temporary extra payment for new drugs, not a permanent VIP status.

CMS pays most non-pass-through separately payable drugs at average sales price (ASP) plus 6 percent (with biosimilar rules that use ASP plus 6 percent or 8 percent of the reference product). Pass-through drugs also use ASP plus 6 percent for acquisition and pharmacy overhead under the CY 2026 OPPS description in MM14361. Those payment formulas matter for reimbursement staff; the coder's job is code, units, modifiers, and status-indicator logic.

When ASP, wholesale acquisition cost, average wholesale price, and mean unit cost are all missing, CY 2026 allows invoice pricing for certain separately payable drugs that meet status indicator and revenue-code conditions, using value code 92. That is a claims-processing workaround for new products, not a reason to skip HCPCS assignment.

JW and JZ: discarded amount versus zero discarded

CMS discarded-drug policy uses two Level II modifiers:

JW has been required since January 1, 2017, to obtain payment for discarded amounts from single-dose containers of separately payable Part B drugs. JZ became required no later than July 1, 2023, to attest that no amount was discarded. Starting October 1, 2023, claims that omit the appropriate modifier may be returned as unprocessable.

The policy applies in the physician office and hospital outpatient settings for drugs incident to physicians' services, and it also applies to Critical Access Hospitals because drugs are separately payable there. It does not apply to Rural Health Clinic or Federally Qualified Health Center visit rates, and it is not used on Inpatient Prospective Payment System (IPPS) inpatient claims.

Hospital OPPS and ASC limits

CMS JW/JZ FAQs state that in the HOPD the modifiers apply to separately payable single-dose-container drugs assigned G or K. In the ASC they apply to separately payable drugs assigned payment indicator K2. They do not apply to OPPS status indicator N or ASC payment indicator N1. The requirement is independent of revenue code; it is not limited to revenue code 0636.

Vaccines described under section 1861(s)(10) of the Social Security Act (influenza, pneumococcal, COVID-19 as specified) are not required to carry JW/JZ, in part because roster billing cannot accommodate modifiers.

Two-line billing when there is discard

When any amount is discarded from a single-dose container of a separately payable drug, bill two lines:

1. Administered units: HCPCS code, no modifier, units administered.
2. Discarded units: same HCPCS code, JW, units discarded.

CMS's own FAQ example: a single-dose container labeled 100 billing units; 95 units administered; 5 units discarded. Report 95 units with no modifier and 5 units with JW. Another CMS example: two 50 mg vials (1 mg = 1 billing unit) used to prepare an 80 mg dose. Report 80 units with no modifier and 20 units with JW.

When nothing is discarded, bill one line with the HCPCS code, JZ, and the administered units. If two 50 mg vials prepare a 100 mg dose with no discard, report 100 units with JZ.

What JW does not do

Overfill—any amount greater than the labeled amount—must not be billed with JW. CMS has prohibited billing overfill since 2011.

If the administered dose is less than one billing unit, CMS does not use fractional units. Report one billing unit with JZ. Do not add a JW line for the unused fraction of that single unit; that would double-pay the unit.

JW and JZ are not for incident-to supplies. Discarded supplies are not payable. Beginning January 1, 2026, CMS pays certain non-BLA skin substitutes as incident-to supplies rather than as Part B drugs. For those products, JZ is not used when the entire package is applied, and discarded unused product must not be billed with JW. Skin substitutes marketed under a biologics license application (BLA) continue to be paid as biologicals; do not mix the two policies.

Document administered and discarded amounts in the medical record. CMS does not prescribe a template, but the claim units must match the record.

Infusion-suite scenario

A hospital outpatient infusion clinic gives a separately payable single-dose-container antiemetic whose HCPCS unit is 1 mg. The labeled vial contains 4 mg. The order is 4 mg, and the nurse administers the entire labeled amount. If Addendum B shows status indicator K or G, report 4 units with JZ. If a later patient receives 3 mg from a 4 mg single-dose vial of a separately payable drug, report 3 units with no modifier and 1 unit with JW, and document the discard. If Addendum B shows N for that same J-code, report the J-code and units the chargemaster needs for cost reporting, but do not append JW or JZ and do not expect a drug APC. Administration time still belongs in CPT (hydration versus therapeutic infusion versus chemotherapy), which is a CPT Medicine skill, not a HCPCS unit skill.

Common traps

Do not apply office-claim JW habits to packaged OPPS N drugs. Do not put JW on the administered line. Do not bill JW for a multi-dose vial. Do not convert milliliters to units without the descriptor. Do not assume a C-code drug is always G; many C-codes package or later convert to J-codes with K or N. Do not use JZ on A4550 or on a skin-substitute supply paid as an incident-to product in 2026.